论文部分内容阅读
目的研究PF方案和mFOLFOX7方案在进展期胃癌新辅助化疗中的近期疗效。方法选取进展期胃癌(均为Ⅲ～Ⅳ期)病例43例,分别采用紫杉醇(PTX)联合5-氟尿嘧淀(5-Fu)/甲酰四氢叶酸钙(LV)(PF方案)和奥沙利铂(L-OHP)联合5-氟尿嘧淀(5-Fu)/甲酰四氢叶酸钙(LV)(mFOLFOX7方案)进行新辅助化疗,14d为一周期,共3周期,观察有效率,手术根治率及毒副反应。结果两组总有效率,手术根治率均无统计学意义(P>0.05)。PF组毒副反应骨髓抑制与脱发较为严重,有统计学意义(P<0.05);mFOLFOX7组神经毒性较突出,有统计学意义(P<0.05)。不同分期患者新辅助化疗效果存在差异,有统计学意义(P<0.05)。结论两方案在进展期胃癌新辅助化疗中的近期疗效无明显差异,毒副反应各有侧重,新辅助化疗的近期疗效Ⅲ期患者明显优于Ⅳ期患者。
Objective To study the short-term effect of PF regimen and mFOLFOX7 regimen in neoadjuvant chemotherapy for advanced gastric cancer. Methods Forty-three patients with advanced gastric cancer (all Ⅲ ~ Ⅳ) were treated with paclitaxel (PTX) combined with 5-fluorouracil / leucovorin (PF) Neoadjuvant chemotherapy was performed with oxaliplatin (L-OHP) combined with 5-Fu / LVF (mFOLFOX7 regimen) for 14 days for 3 cycles Efficacy, radical cure rate and toxic side effects. Results The total effective rate and radical cure rate were not statistically significant (P> 0.05). The bone marrow suppression and alopecia in the PF group were more serious with statistical significance (P <0.05). The neurotoxicity in the mFOLFOX7 group was more prominent (P <0.05). Neoadjuvant chemotherapy in patients with different staging differences were statistically significant (P <0.05). Conclusion There is no significant difference between the two regimens in neoadjuvant chemotherapy for advanced gastric cancer. The side effects of neoadjuvant chemotherapy are better than those in stage Ⅳ.